Deep Learning Signature for Predicting the Novel Grading System of

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02898857` - Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma	N/A
Completed	`NCT02127359` - Whole-Exome Sequencing (WES) of Cancer Patients
Recruiting	`NCT01249066` - Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma	N/A
Not yet recruiting	`NCT04482829` - TCM in the Treatment of Lung Adenocarcinoma	N/A
Recruiting	`NCT04929041` - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Phase 2/Phase 3
Terminated	`NCT04691375` - A Study of PY314 in Subjects With Advanced Solid Tumors	Phase 1
Terminated	`NCT02621333` - Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma	Phase 2
Active, not recruiting	`NCT02282267` - Blood Detection of EGFR Mutation For Iressa Treatment	N/A
Not yet recruiting	`NCT01942629` - Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas	N/A
Recruiting	`NCT01482585` - Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy	N/A
Recruiting	`NCT03376737` - Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma	Phase 2
Recruiting	`NCT05537922` - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Recruiting	`NCT04937283` - Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm	N/A
Recruiting	`NCT06255197` - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Completed	`NCT02093000` - A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma	N/A
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Terminated	`NCT04682431` - A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase 1
Enrolling by invitation	`NCT05136014` - Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Terminated	`NCT05012397` - Milademetan in Advanced/Metastatic Solid Tumors	Phase 2
Recruiting	`NCT05266846` - Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK	Phase 2

NCT number	NCT05736991
Study type	Observational
Source	Shanghai Pulmonary Hospital, Shanghai, China
Contact
Status	Recruiting
Phase
Start date	November 1, 2022
Completion date	April 30, 2023

Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms